about
Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growthAmiloride enhances antigen specific CTL by faciliting HBV DNA vaccine entry into cellsViral vaccines for farmed finfishExpression library immunization: a road map for discovery of vaccines against infectious diseasesEnhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein-pseudotyped HIV-1 GTargeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency.Asthma, airway biology, and allergic rhinitis in AJRCCM 2000.DNA/MVA Vaccines for HIV/AIDSIn vitro and in vivo characterization of DNA delivery using recombinant Lactococcus lactis expressing a mutated form of L. monocytogenes Internalin A.Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention.Targeting plasmid-encoded proteins to the antigen presentation pathways.Optimization and delivery of plasmid DNA for vaccination.Genetic immunization with Hantavirus vaccine combining expression of G2 glycoprotein and fused interleukin-2Mucosal adjuvanticity of a Shigella invasin complex with dna-based vaccinesA DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy.Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits.DNA vaccines: a rational design against parasitic diseases.Nucleic acid vaccination strategies against infectious diseases.DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.Stable antigen is most effective for eliciting CD8+ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus in vivo.Immunotherapy of cancers comes of age.Immunogenicity and efficacy of a bivalent DNA vaccine containing LeIF and TSA genes against murine cutaneous leishmaniasis.Immunogenicity and protective efficacy of DNA vaccine against visceral leishmaniasis in BALB/c miceCodelivery of DNA vaccination encoding LeIF gene and IL-12 increases protection against Leishmania major infection in BALB/c mice.Chitosan-plasmid nanoparticle formulations for IM and SC delivery of recombinant FGF-2 and PDGF-BB or generation of antibodies.A cDNA Immunization Strategy to Generate Nanobodies against Membrane Proteins in Native Conformation.In vivo electroporation of a new gene vaccine encoding ten repeats of Aβ3-10 prevents brain Aβ deposition and delays cognitive impairment in young Tg-APPswe/PSEN1dE9 mice.Clostridium perfringens beta toxin DNA prime-protein boost elicits enhanced protective immune response in mice.Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.Leishmania vaccines: from leishmanization to the era of DNA technology
P2860
Q24794166-BF49131B-13F1-4129-BEC5-8317B316B48BQ28481556-699AAB58-076A-43C2-97C0-2563633B7C41Q30564097-84BE4049-E109-4A76-8F19-F613394B3143Q33225644-26FFE874-F95D-43BF-ADE7-C0F71C58E1D3Q34342982-37FE4E6F-C2FB-4485-A2FD-A9491CBF7CFFQ34382810-6F036192-0756-4C71-945F-05B9B8DFEB69Q34446626-0289A838-6EF2-4776-A748-5A2050CCF0B8Q34492802-DA8C72E5-ADE9-4714-B91E-485023FF329AQ34518201-150137E1-7CAF-4B39-A890-5ADA72ECB7A9Q35156471-193D3C91-1FFF-4073-94DC-70164D9B21F9Q35826370-8EC0DF8B-865B-4B41-9E0B-525AD8134D0FQ36690285-D4D5C4AC-E71F-496D-B7B4-096145C45D7EQ36958845-4A5E6F01-AFD9-424D-9BFA-B85D66368E7FQ37156758-1445A5B6-BC99-4EB9-92B3-454FF10510DCQ37258250-9C2D329A-CF95-403A-BDE5-9E3EA7C49C56Q37264651-4E69FA1F-2A69-4C9C-B4BB-0ECA98ABACB2Q37438261-AF228347-84B4-41A3-97CC-40E9A5863130Q37505351-D16BAB5A-FC22-4C7D-8A3E-2D4CFFEC9E98Q37682900-E634339F-7313-4922-9DF0-CB75CF2B838CQ38586079-2F3277D2-6A14-426F-A01C-4AFD6B266E73Q38786910-A0F051AE-58A7-4DCD-AA7C-AD95E19A6692Q38853141-3763774C-7AE6-4A02-8A28-717B9F6F9AC6Q39320211-BD61F6D3-B776-4A24-8A33-588531DAA71EQ40099075-13926850-AC36-40BC-B009-D5AB4D1A985AQ40319505-83955692-FCBF-4B6C-AA50-01219ECFBF82Q40572422-46EA1A22-C356-45C5-9AC5-459ED8AE036AQ40794947-34074144-AFBE-445E-8FAE-B1FFE17C4090Q45885233-4C045E1A-BBF3-47E4-A06C-7371B743F950Q48509449-B6262875-9E97-4142-B359-D4D61838EBBDQ48603497-A09C3FF1-4992-4B82-A651-A47898B3072CQ50639945-C8DCAADA-AFA7-429C-BC77-FC428B6624C9Q55154648-9E840052-7036-410E-B68B-26BD2DB1BA75Q56157155-6F2910E4-4094-4229-AFEE-C0E3B2233756
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antigen presentation and DNA vaccines.
@ast
Antigen presentation and DNA vaccines.
@en
Antigen presentation and DNA vaccines.
@nl
type
label
Antigen presentation and DNA vaccines.
@ast
Antigen presentation and DNA vaccines.
@en
Antigen presentation and DNA vaccines.
@nl
prefLabel
Antigen presentation and DNA vaccines.
@ast
Antigen presentation and DNA vaccines.
@en
Antigen presentation and DNA vaccines.
@nl
P2093
P2860
P1476
Antigen presentation and DNA vaccines.
@en
P2093
P2860
P304
P356
10.1164/AJRCCM.162.SUPPLEMENT_3.15TAC10
P407
P433
P577
2000-10-01T00:00:00Z